0-850-8855519

Yayınlar

Prof. Dr. Hakan Leblebicioğlu

Prof. Dr. Hakan Leblebicioğlu’nun ulusal dergilerde yayınlanmış 76 makalesi, uluslararası dergilerde basılmış 187 yayını, 21 kitap editörlüğü ve 56 kitap bölümü mevcuttur. Altı uluslararası kitapta bölüm yazarıdır. Emerging and re-emerging infections in travellers kitabının editörüdür.

Yayınlarına Science Citation Index (SCI) kapsamındaki dergilerde 6.023 atıf yapılmıştır. H indeksi 42’dir.

 

Uluslararası Kitap Editörlüğü

  1. Leblebicioglu H, Beeching N, Eskild P. Emerging and Re-emerging Infections in Travellers. Switzerland: Springer Cham, 2024.

Uluslararası Kitap Bölümleri

  1. Leblebicioglu H. Crimean-Congo hemorrhagic fever. In: Hirsch MA, ed. UpToDate. Waltham, MA.: UpToDate; 2018.
  2. Rojek A, Carson G, Kato Y, Horby PW, Leblebicioglu H. Viral Hemorrhagic Fevers. In: Cohen J, Powderly WG, Opal SM. (eds) Infectious Diseases. 4. Ed. Elsevier. 2017:1110–1118.e2
  3. Leblebicioglu H. Crimean-Congo hemorrhagic fever. In: Kasper, DL., Fauci, AS., Hauser, SL., Longo, DL.., Jameson, JL. Loscalzo, J. (eds) Harrison’s Principles of Internal Medicine Updates. 19th Ed. Updates. New York: McGraw Hill Education.
  4. Pshenichnaya N., Chulanov V., Leblebicioglu H. Epidemiology of Hepatitis B. In: Ozaras R., Tahan V. (eds) Viral Hepatitis: Chronic Hepatitis B. Springer, Cham. 2018.
  5. Chulanov V., Pshenichnaya N., Leblebicioglu H. Genetic Diversity of the Hepatitis B Virus and Its Epidemiological Significance. In: Ozaras R., Tahan V. (eds) Viral Hepatitis: Chronic Hepatitis B. Springer, Cham. 2018.
  6. Ozaras, R., Leblebicioglu H. Global Epidemiology of Hepatitis C Virus Infection.. In: Ozaras R., Salmon-Ceron D. (eds) Viral Hepatitis: Chronic Hepatitis C. Springer, Cham. 2019.

Seçilmiş Yayınlar

  1. Vahaboglu H, Ozturk R, Aygun G, Coskunkan A, Yaman A, Kaygusuz A, Leblebicioglu H, Balik I, Aydin K, Otkun M. Widespread detection of PER-1 type extended spectrum b-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 1997;41:2265-2269.
  2. Leblebicioglu H, Gunaydin M, Esen S, Tuncer I, Fındık D, Ural O, Saloglu N, Yaman A, Tasova Y. Surveillance of antimicrobial resistance in gram-negative isolates from intensive care units in Turkey: analysis of data from the last 5 years. J Chemother 2002; 14 (2): 140-146.
  3. Leblebicioglu H, Esen S and Turkish Nosocomial Urinary Tract Infection Study Group. Hospital-acquired urinary tract infections in Turkey: a nationwide multicenter point prevalence study. J Hosp Infect 2003; 53: 207-210.
  4. Leblebicioglu H. Clinical aspects of chronic hepatitis C infection. JAMA 2003; 290(11):1453.
  5. Peksen Y, Canbaz S, Leblebicioglu H, Sunbul M, Esen S, Sunter AT. Primary care physicians’ approach to diagnosis and treatment of hepatitis B and hepatitis C patients.  BMC Gastroenterol 2004; 4 (1): 3.
  6. Sunbul M, Leblebicioglu H, and Hepatitis Study Group. Distribution of hepatitis B virus genotypes in patients with chronic hepatitis B in Turkey. World J Gastroenterol 2005 7;11(13):1976-80.
  7. Leblebicioglu H, Yilmaz H, Tasova Y, Alp E, Saba R, Caylan R, Bakir M, Akbulut A, Arda B, Esen S and Study Group (Cagatay A, Ergin F, Bodur H, Sahin GS, Sencan I, Gurcan S, Doyuk E, Mete B, Oncul O).  Characteristics and analysis of risk factors for mortality in infective endocarditis.  Eur J Epidemiol 2006;21(1):25-31.
  8. Rosenthal VD, Maki DG, Salomao R, Moreno CA, Mehta Y, Higuera F, Cuellar LE, Arikan OA, Abouqal R, Leblebicioglu H; International Nosocomial Infection Control Consortium. Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. Ann Intern Med 2006; 145 (8): 582-591.
  9. Leblebicioglu H, Rosenthal VD, Arikan OA, Ozgultekin A, Yalcin AN, Koksal I, Usluer G, Sardan YC, Ulusoy S; the Turkish Branch of INICC. Device-associated hospital-acquired infection rates in Turkish intensive care units. Findings of the International Nosocomial Infection Control Consortium (INICC). J Hosp Infect 2007; 65 (3): 251-257.
  10. Leblebicioglu H, Esen S, Turan D, Tanyeri Y, Karadenizli A, Ziyagil F, Goral G. Outbreak of tularemia: a case-control study and environmental investigation in Turkey. Int J Infect Dis 2008;12(3):265-269.
  11. Rosenthal VD, Maki DG, Mehta A, Alvarez-Moreno C, Leblebicioglu H, Higuera F, Cuellar LE, Madani N, Mitrev Z, Dueñas L, Navoa-Ng JA, Garcell HG, Raka L, Hidalgo RF, Medeiros EA, Kanj SS, Abubakar S, Nercelles P, Pratesi RD; International Nosocomial Infection Control Consortium Members. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control 2008;36(9):627-37.
  12. Ulger F, Esen S, Dilek A, Yanik K, Gunaydin M, Leblebicioglu H. Are we aware how contaminated our mobile phones with nosocomial pathogens? Ann Clin Microbiol Antimicrob 2009;8:7.
  13. Leblebicioglu H. Crimean-Congo haemorrhagic fever in Eurasia. Int J Antimicrob Agents 2010;36:S43-S46.
  14. Ascioglu S, Leblebicioglu H, Vahaboglu H, Chan KA. Ribavirin for patients with Crimean-Congo haemorrhagic fever: a systematic review and meta-analysis. J Antimicrob Chemother 2011;66(6):1215-1222.
  15. Alp E, Leblebicioglu H, Doganay M, Voss A. Infection control practice in countries with limited resources. Ann Clin Microbiol Antimicrob 2011;22;10:36.
  16. Leblebicioglu H. Enterohemorrhagic Escherichia coli Epidemic: The Sensitive Role of the Media in the Handling of Epidemics. Clinical Infectious Diseases 2012;54:450-451.
  17. Leblebicioglu H, Bodur H, Dokuzoguz B, Elaldi N, Guner R, Koksal I, Kurt H, Senturk GC. Case Management and Supportive Treatment for Patients with Crimean-Congo Hemorrhagic Fever. Vector Borne Zoonotic Dis 2012;12(9):805-11.
  18. Akıncı E, Bodur H, Leblebicioglu H. Pathogenesis of Crimean-Congo Hemorrhagic Fever. Vector Borne Zoonotic Dis 2013;13(7):429-37.
  19. Leblebicioglu H, Arama V, Causse X, Marcellin P, Ozaras R, Postawa-Klozinska B, Simon K, Suceveanu AI, Wiese M, Zeuzem S, Klauck I, Morais E, Bjork S, Lescrauwaet B, Kamar D, Zarski JP; The AI463-121 European Longitudinal Chronic Hepatitis B Study Group. Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countries. J Viral Hepat 2014;21(9):662-70.
  20. Leblebicioglu H, Eroglu C, Erciyas-Yavuz K, Hokelek M, Acici M, Yilmaz H. Role of migratory birds in spreading Crimean-Congo hemorrhagic fever, Turkey. Emerg Infect Dis 2014;20(8):1331-4.
  21. Leblebicioglu H, Erben N, Rosenthal VD, Sener A, Uzun C, Senol G, Ersoz G, Demirdal T, Duygu F, Willke A, Sirmatel F, Oztoprak N, Koksal I, Oncul O, Gurbuz Y, Güçlü E, Turgut H, Yalcin AN, Ozdemir D, Kendirli T, Aslan T, Esen S, Ulger F, Dilek A, Yilmaz H, Sunbul M, Ozgunes I, Usluer G, Otkun M, Kaya A, Kuyucu N, Kaya Z, Meric M, Azak E, Yýlmaz G, Kaya S, Ulusoy H, Haznedaroglu T, Gorenek L, Acar A, Tutuncu E, Karabay O, Kaya G, Sacar S, Sungurtekin H, Uğurcan D, Turhan O, Kaya S, Gumus E, Dursun O, Geyik MF, Şahin A, Erdogan S, Ince E, Karbuz A, Çiftçi E, Taşyapar N, Güneş M. Surgical site infection rates in 16 cities in Turkey: findings of the International Nosocomial Infection Control Consortium (INICC). Am J Infect Control 2015;43(1):48-52.
  22. Leblebicioglu H, Sunbul M, Memish ZA, Al-Tawfiq JA, Bodur H, Ozkul A, Gucukoglu A, Chinikar S, Hasan Z. Consensus report: Preventive measures for Crimean-Congo Hemorrhagic Fever during Eid-al-Adha festival. Int J Infect Dis 2015;38:9-15.
  23. Leblebicioglu H, Ozaras R. Syrian refugees and infectious disease challenges. Travel medicine and Infectious Disease 2015;13(6)443-4.
  24. Leblebicioglu H, Ozaras R, Irmak H, Sencan I. Crimean-Congo hemorrhagic fever in Turkey: current status and future challenges. Antiviral Research 2016;126:21-34.
  25. Al-Abri SS, Abaidani IA, Fazlalipour M, Mostafavi E, Leblebicioglu H, Pshenichnaya N, Memish ZA, Hewson R, Petersen E, Mala P, Nhu Nguyen TM, Rahman Malik M, Formenty P, Jeffries R. Current status of Crimean-Congo haemorrhagic fever in the World Health Organization Eastern Mediterranean Region: issues, challenges, and future directions. Int J Infect Dis 2017;58:82-89.
  26. Fletcher TE, Gulzhan A, Ahmeti S, Al-Abri SS, Asik Z, Atilla A, Beeching NJ, Bilek H, Bozkurt I, Christova I, Duygu F, Esen S, Khanna A, Kader Ç, Mardani M, Mahmood F, Mamuchishvili N, Pshenichnaya N, Sunbul M, Yalcin TY, Leblebicioglu H. Infection prevention and control practice for Crimean-Congo hemorrhagic fever-A multi-center cross-sectional survey in Eurasia. PLoS One 2017;12(9): e0182315
  27. Leblebicioglu H, Arends JE, Ozaras R, Corti G, Santos L, Boesecke C, Ustianowski A, Duberg AS, Ruta S, Salkic NN, Husa P, Lazarevic I, Pineda JA, Pshenichnaya NY, Tsertswadze T, Matičič M, Puca E, Abuova G, Gervain J, Bayramli R, Ahmeti S, Koulentaki M, Kilani B, Vince A, Negro F, Sunbul M, Salmon D; ESGHV (part of ESCMID). Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. Antiviral Res 2018;150:9-14.
  28. Faria LC, Terrabuio DRB, Leblebicioglu H, Huprikar S. Viral Hepatitis Recommendations for Solid-Organ Transplant Recipients and Donors. Transplantation 2018;102(2S Suppl 2):S66-S71.
  29. Fletcher TE, Leblebicioglu H, Bozkurt I, Sunbul M, Bilek H, Asik Z, Barut S, Gunes F, Gemici U, Hewson R, Wilson D, O’Shea MK, Woolley T, Faragher B, Parmar K, Lalloo DG, Beeching NJ, Hunt BJ. Rotational thromboelastometry alongside conventional coagulation testing in patients with Crimean-Congo haemorrhagic fever: an observational cohort study. Lancet Infect Dis 2019;19(8):862-871.